Fulvestrant is primarily used in postmenopausal women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. It is often prescribed for patients whose cancer has progressed following treatment with other endocrine therapies like tamoxifen or aromatase inhibitors. In some cases, fulvestrant may also be used in combination with other drugs such as CDK4/6 inhibitors to enhance its efficacy.
